文献速递中医内科中药与中成药合理使用

扶正化瘀方及其活性成分通过促进TOMM34基因表达抑制HBV感染肝细胞产生HBeAg

Fuzheng Huayu Recipe and its active compounds inhibited HBeAg production by promoting TOMM34 gene expression in HBV-infected hepatocytes.
PubMed 文献 · Front Pharmacol · 2022-09-26

本研究探讨扶正化瘀方(FZHY)抑制HBeAg产生的分子机制。临床数据显示FZHY+恩替卡韦(ETV)组48周后血清HBeAg滴度下降程度显著高于ETV组;体内外实验证实FZHY可降低HBeAg并促进HBeAg血清学转换,其机制与促进TOMM34基因表达有关,活性成分槲皮素、黄芩苷和虫草素亦有类似作用。

要点

  • FZHY联合ETV较单用ETV可更显著降低血清HBeAg滴度。
  • FZHY在HBV转基因小鼠中降低HBeAg并促进HBeAg血清学转换。
  • 槲皮素、黄芩苷和虫草素可促进TOMM34表达而减少HBeAg产生。

核心结论

  • FZHY及其活性成分槲皮素、黄芩苷和虫草素可通过促进TOMM34基因表达抑制HBV感染肝细胞产生HBeAg。

研究设计与样本

  • 临床数据分析比较FZHY+ETV组与ETV组患者血清HBeAg滴度下降程度。
  • 体内实验采用C57BL/6N-Tg(1.28HBV)/Vst HBV转基因小鼠。
  • 对FZHY中20种活性化合物进行药理筛选实验。

主要发现

  • 临床研究显示FZHY+ETV组治疗48周后血清HBeAg滴度下降程度显著高于ETV组。
  • 体内实验显示FZHY可显著降低HBV转基因小鼠血清HBeAg滴度并促进HBeAg血清学转换。
  • 体外实验显示FZHY可依赖性降低HBeAg滴度,但未显著抑制HBsAg和HBV-DNA表达。
  • 细胞实验发现TOMM34可能是FZHY抑制HBeAg产生的关键靶点。
  • 药理筛选显示槲皮素、黄芩苷和虫草素可促进TOMM34基因表达并减少HBeAg产生。

临床怎么用

  • 在HBV相关肝纤维化或肝硬化抗病毒治疗中,可考虑FZHY联合ETV以增强HBeAg滴度下降效果。
  • FZHY及其活性成分槲皮素、黄芩苷和虫草素可能通过调控TOMM34表达发挥抗HBeAg作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and aim: Fuzheng Huayu Recipe (FZHY) is a Chinese patent medicine (approval No. Z20020074) included in the national medical insurance catalogue, which is mainly used for anti-hepatic fibrosis treatment of hepatitis B virus (HBV) induced liver fibrosis and liver cirrhosis. In clinical practice, we discovered that FZHY might also have a direct anti-HBV effect on inhibiting HBeAg production, but the mechanism underlying was unclear. This study aimed to clarify the molecular mechanism of the inhibition effect of FZHY on HBeAg production. Methods: The decrease degree of serum HBeAg titer in FZHY + entecavir (ETV) group patients were analyzed through clinical data. C57BL/6N-Tg (1.28HBV)/Vst HBV transgenic mice were used for in vivo experiments. HepG2. 2.15 cells (wild-type HBV replication cells) were used for in vitro experiments. Results: The clinical study results showed that the decrease degree of serum HBeAg titer in FZHY+ETV group was significantly higher than that in ETV group after 48 weeks treatment. In vivo experiments results showed that FZHY could significantly reduce the serum HBeAg titer in HBV transgenic mice, and promote HBeAg seroconversion. In vitro experiments results showed that FZHY could reduce HBeAg titer dependently, but it did not significantly inhibit the expression of HBsAg and HBV-DNA. Further cell experiments in vitro discovered that TOMM34 might be the key target for FZHY to inhibit HBeAg production. The subsequent pharmacological screening experiment of 20 active compounds in FZHY showed that quercetin, baicalin and cordycepin could promote the expression of TOMM34 gene and reduce the production of HBeAg. Conclusion: In conclusion, FZHY and its active compounds quercetin, baicalin and cordycepin could inhibit HBeAg production by promoting the expression of TOMM34 gene in HBV-infected hepatocytes.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xing L, Zeng R, Huang K, et al. Fuzheng Huayu Recipe and its active compounds inhibited HBeAg production by promoting TOMM34 gene expression in HBV-infected hepatocytes. Front Pharmacol. 2022. PMID: 36249820. doi:10.3389/fphar.2022.907921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。